
Dr. Mukesh Patekar is an experienced Medical Oncologist serving as Associate Director – Medical Oncology at BLK-Max Super Speciality Hospital, New Delhi. With more than 20 years of professional experience, he specialises in the medical treatment of solid tumours, blood cancers and complex malignancies.
He completed his MBBS from RCSM Government Medical College, Kolhapur, in 2008, followed by an MD in General Medicine from AIIMS, New Delhi, in 2011. He subsequently obtained a DM in Medical Oncology from AIIMS in 2018 and also holds a DNB in Medical Oncology.
His clinical expertise includes breast and thoracic oncology, gastrointestinal cancers, hepatopancreatobiliary malignancies, gynaecological and genitourinary cancers, lymphomas and leukaemias. He also specialises in immunotherapy, targeted therapy, precision oncology and the management of selected paediatric malignancies.
Before joining BLK-Max, Dr. Patekar served as Unit Head and Senior Consultant in Medical Oncology at Artemis Hospitals, Gurugram, and held consultant positions at Fortis Memorial Research Institute. He is associated with the American Society of Clinical Oncology, European Society for Medical Oncology and Indian Society for Medical and Paediatric Oncology.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Mukesh Patekar for Hematology & BMT treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Hematology & BMT in India.
Dr. Mukesh Patekar regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Mukesh Patekar holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in Hematology & BMT.
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
AML, CML, CLL, ALL, Hodgkin & Non-Hodgkin Lymphoma, Multiple Myeloma — treated with chemotherapy, targeted therapy & BMT.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders.
Cutting-edge immunotherapy using genetically modified T-cells for blood cancers that have relapsed after standard treatments.
Curative BMT for thalassemia major and sickle cell anemia in children and adults. Low-cost programs available across India.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
HSCT (Hematopoietic Stem Cell Transplant) for aggressive Multiple Sclerosis — a disease-modifying treatment available in India.
Expert care for childhood leukemia, thalassemia, ITP, and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with modern protocols.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and coagulopathies.
The most complex and potentially curative form of BMT where stem cells come from a matched donor. Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested and reinfused after high-dose chemotherapy. Used for multiple myeloma and relapsed lymphomas.
Revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation.
Personalised chemotherapy and next-generation targeted agents for lymphoma, leukaemia, and related disorders.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.